www.heart.org·4 min read·hard
GLP-1-based meds linked to fewer heart events in adults with obesity, autoimmune disease
✦AI Summary
A new study presented at the American Diabetes Association sessions indicates that GLP-1 receptor agonist medications may reduce the risk of serious cardiac events in patients with both obesity and autoimmune diseases. The findings suggest potential cardiovascular benefits for this high-risk population.
Why it matters
This research could influence clinical treatment guidelines for patients managing complex, comorbid health conditions.
Embargoed until 12:30 p.m. CT/1:30 p.m. ET Saturday, June 6
healthscience
Political Bias
Center
LeftLean LCenterLean RRight
Confidence: 90%
The content is a summary of peer-reviewed medical research findings.
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in